The Canadian Lipoprotein (a) Registry: a prospective multisite observational study to optimize the care of patients with inherited risk of cardiovascular disease, Canada

Registration Status: Completed

Objective: Lp(a) Registry is designed as a biobank focused on prospective, longitudinal study of patients with elevated Lp(a) levels and assessing their co-existing cardiovascular risk factors and their management. The ultimate goal of the registry is to understand the characteristics, patterns of treatment, and clinical outcomes, and determinants of risk of Canadian patients with elevated Lp(a). Participants will be recruited at 3 centers, with Healthy Heart Program at St. Pauls Hospital, Vancouver as main center; the other 2 centers are cardiac Clinics also located in Vancouver. Once, Registry is established here in BC, the other centers across BC and Canada will join. Participants will be enrolled in the study indefinitely and therefore data collected longitudinally coincide with clinically-indicated visits. Clinical data, laboratory results, cardiovascular events and imaging data will be collected.

Registered Biobank Name	The Canadian Lipoprotein (a) Registry: a prospective multisite observational study to optimize the care of patients with inherited risk of cardiovascular disease
Biobank Leader	Luba Cermakova
Country	Canada
Email for biobank inquiries	lcermakova@providencehealth.bc.ca
Principal Investigator	Dr. Liam Brunham
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).